- Global Pharma News & Resources

GABA Transaminase Inhibitor Drug Pipeline Research Report 2022 -

DUBLIN--(BUSINESS WIRE)--The "GABA Transaminase Inhibitor - Pipeline Insight, 2022" clinical trials has been added to's offering.

"GABA Transaminase Inhibitor - Pipeline Insight, 2022" report by the publisher offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across GABA Transaminase Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for GABA Transaminase Inhibitor

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for GABA Transaminase Inhibitor

The report assesses the active GABA Transaminase Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.

Reasons to Buy

  • Establish a comprehensive understanding of the current pipeline scenario across GABA Transaminase Inhibitor to formulate effective R&D strategies
  • Assess challenges and opportunities that influence GABA Transaminase Inhibitor research & development (R&D)
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify and understand the sought after therapy areas and indications for GABA Transaminase Inhibitor
  • Identify the product attributes and use it for target finding, drug repurposing, and precision medicine
  • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for GABA Transaminase Inhibitor to enhance and expand business potential and scope
  • Plan prospective mergers and acquisitions effectively by identifying key players in this area and their most promising pipeline therapeutics and developmental progress
  • The extensive domain knowledge on therapy areas supports the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

Key Topics Covered:

1. Report Introduction

2. GABA Transaminase Inhibitor - Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for GABA Transaminase Inhibitor

4. Comparative Analysis

5. GABA Transaminase Inhibitor Pipeline Products in Clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

6. GABA Transaminase Inhibitor Pipeline Products in Non-clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment: Active Products

  • Pipeline Assessment by Route of Administration
  • Pipeline Assessment by Stage and Route of Administration
  • Pipeline Assessment by Molecule Type
  • Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

  • Product Description
  • Research and Development
  • Product Development Activities
  • Reason for dormancy/discontinuation


Companies Mentioned

  • sanofi-aventis
  • Catalyst Pharmaceutical Partners
  • Banner Life Sciences
  • Banner Pharmacaps
  • BioLink Life Sciences
  • Kowa

For more information about this clinical trials report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 03-Feb-2022